Repligen Enhances Bioprocessing Capabilities With Acquisition From 908 Devices
$MASS
In a significant development within the bioprocessing industry, Repligen Corporation (Nasdaq:RGEN) has acquired a portfolio of desktop devices designed for process analytical technology (PAT) applications from 908 Devices Inc. (Nasdaq:MASS). This strategic acquisition is valued at $70 million in cash. The transaction encompasses four key devices: MAVERICK and MAVEN, which are integral for real-time monitoring and control of bioprocess parameters REBEL, an at-line cell culture media analyzer and ZipChip, a device used for high-resolution sample separations.
Olivier Loeillot, President and CEO of Repligen, expressed enthusiasm about the integration of 908 Devices’ bioprocessing team and their technologies into Repligen’s operations. He highlighted the acquisition as a win-win for both companies, enhancing Repligen’s ability to serve a broader range of modalities with advanced analytics solutions.
This move is anticipated to drive greater efficiencies in the development and manufacturing processes of biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) globally. Meanwhile, 908 Devices will continue to focus on the expansion of its handheld device portfolio, which plays a crucial role in health and safety applications by facilitating advanced chemical detection at the point of need.
Kevin J. Knopp, CEO and Co-founder of 908 Devices, wished Repligen continued success and emphasized the ongoing commitment of his company to innovate in chemical analysis. The acquisition not only signifies Repligen’s commitment to embedding digitization technologies in bioprocessing but also aligns with the industry’s broader trend towards more integrated and efficient production systems.
By enhancing real-time monitoring and control capabilities, Repligen is poised to meet the increasing demands for faster and more reliable biopharmaceutical manufacturing processes. This strategic move by Repligen could reshape the competitive landscape of the bioprocessing industry, offering more robust and integrated solutions that could set new standards for efficiency and quality in biopharmaceutical production.
**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**